Recent news highlights Corcept Therapeutics' strong Q2 2026 earnings and revenue growth, a raised 2026 outlook, and stock price gains reaching 52-week highs. The company is recognized among top biotech gainers with positive market sentiment.

• Corcept Therapeutics reported Q2 2026 earnings and revenues surpassing prior year levels, with net product revenue of $256.1 million and net income of $43.0 million [N6][N7].
• The company raised its 2026 outlook following strong quarterly results, reflecting confidence in ongoing commercial performance [N2][N6].
• Corcept's stock price increased by 30%, contributing to its position among biotech stocks at 52-week highs [N1].
• Q2 earnings call highlighted operational progress and commercial execution supporting growth [N8].
• Market coverage notes Corcept as a top biotech gainer alongside peers, with positive investor interest [N2].

Corcept's recent product launches and clinical trial successes demonstrate its ability to expand treatment options for patients with hypercortisolism and certain cancers. The company's strong revenue growth and improved operating income reflect effective commercialization and market acceptance. Its robust liquidity position supports ongoing research and development and commercial activities. Continued clinical progress and market expansion could enhance its product portfolio and revenue streams.

Corcept faces risks including regulatory changes, pricing pressures, and reimbursement challenges that could affect product sales and profitability. The company's reliance on a limited number of products exposes it to market and competitive risks. High operating expenses, including stock-based compensation and selling costs, may pressure margins. Clinical trial outcomes and regulatory approvals for pipeline products remain uncertain. Market volatility and stock price fluctuations may impact investor sentiment.

Corcept's moat derives from its proprietary portfolio of selective cortisol modulators, including patented compounds and FDA-approved products with established commercial presence. Its specialized distribution network, patient support programs, and clinical research initiatives support market penetration and patient access. Regulatory approvals and exclusivity for its products, including Lifyorli's recent approval, contribute to competitive positioning. However, the pharmaceutical industry faces regulatory, reimbursement, and competitive risks that can impact product adoption and pricing.

• Regulatory and Reimbursement Risks: Changes in laws, regulations, or reimbursement policies could adversely affect pricing, insurance coverage, and sales of Corcept's products.
• Product Concentration: Dependence on a limited number of products, primarily Korlym and Lifyorli, exposes the company to risks if sales decline or competition increases.
• Clinical and Development Risks: Clinical trial results and regulatory approvals for pipeline products are uncertain and could impact future growth.
• Financial and Market Risks: High operating expenses and stock-based compensation may pressure profitability. Market volatility can affect stock performance and capital raising.

• Corcept Therapeutics is a commercial-stage pharmaceutical company focused on discovery, development, and commercialization of medications that modulate cortisol effects to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders [S1].
• The company has a single reportable segment and sells products primarily in the United States [S1].
• Corcept's main marketed products include Korlym and its authorized generic version for hypercortisolism (Cushing's syndrome), and Lifyorli (relacorilant), approved in March 2026 for certain ovarian and related cancers, launched in April 2026 [S1].
• Korlym and its authorized generic are sold through specialty pharmacies and distributors, with direct sales to patients and hospitals [S1].
• Revenue recognition occurs when control transfers to customers, either patients or specialty distributors, and collection is probable [S1].
• The company has patient support programs and charitable donations to ensure access to medications regardless of financial status [S1].
• Corcept conducts clinical research, including the CATALYST study on hypercortisolism prevalence in difficult-to-control type 2 diabetes patients, which met primary and secondary endpoints showing efficacy of Korlym [S1].
• Net product revenue for Q2 2026 was $256.1 million, up from $194.4 million in Q2 2025, driven by higher sales of Hypercortisolism Products and Lifyorli's launch [S1].
• Net product revenue for the six months ended June 30, 2026 was $421.1 million, compared to $351.6 million for the same period in 2025 [S1].
• Cost of sales for Q2 2026 was $4.1 million, with research and development expenses of $53.9 million and selling, general and administrative expenses of $156.9 million [S1].
• Income from operations for Q2 2026 was $41.3 million, compared to $26.7 million in Q2 2025 [S1].
• Net income for Q2 2026 was $43.0 million, with basic EPS of $0.40 and diluted EPS of $0.36 [S1].
• As of June 30, 2026, Corcept had cash and cash equivalents of $111.0 million and short-term investments of $197.2 million, with a current ratio of 2.86 and cash ratio of 2.0, indicating strong liquidity [S1].
• The company has operating leases for office space with right-of-use assets and lease liabilities recorded, with lease expense detailed in filings [S1].
• Stock-based compensation is a significant expense component, with $52.5 million recorded in the six months ended June 30, 2026 [S1].
• Corcept is a large accelerated filer and is not a shell company [S1].
• The company has a stock repurchase program but did not repurchase shares in the recent quarter [S1].
• Recent news highlights include strong Q2 earnings and revenue growth, a raised 2026 outlook, and stock price gains reaching 52-week highs [N1][N2][N6][N7][N8].